Literature DB >> 16411124

Bacteremic pneumococcal pneumonia associated with macrolide failure.

J Dylewski1, R Davidson.   

Abstract

Despite rising rates of macrolide resistance to Streptococcus pneumoniae, the current guidelines for outpatient treatment of community-acquired pneumonia include a macrolide as initial empiric therapy. There have only been a few previously documented cases of macrolide treatment failure in community-acquired pneumonia and there is controversy as to whether macrolide resistance in S. pneumoniae is clinically important. Reported here are two cases of community-acquired pneumonia caused by S. pneumoniae, one of which was fatal, that failed to respond to clarithromycin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16411124     DOI: 10.1007/s10096-005-0081-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.

Authors:  Michael R Jacobs
Journal:  Clin Infect Dis       Date:  2002-08-09       Impact factor: 9.079

3.  Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.

Authors:  D J Hoban; A K Wierzbowski; K Nichol; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Detection of erythromycin-resistant determinants by PCR.

Authors:  J Sutcliffe; T Grebe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams.

Authors:  D Van Kerkhoven; W E Peetermans; L Verbist; J Verhaegen
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

6.  Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.

Authors:  John R Lonks; Javier Garau; Lucía Gomez; Mariona Xercavins; Anna Ochoa de Echagüen; Ilana F Gareen; Philip T Reiss; Antone A Medeiros
Journal:  Clin Infect Dis       Date:  2002-08-09       Impact factor: 9.079

7.  In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.

Authors:  Jeff Powis; Allison McGeer; Karen Green; Otto Vanderkooi; Karl Weiss; George Zhanel; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Ross Davidson; Kevin Forward; Daryl Hoban; Andrew Simor; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 8.  Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.

Authors:  Thomas M File; Javier Garau; Francesco Blasi; Christian Chidiac; Keith Klugman; Hartmut Lode; John R Lonks; Lionel Mandell; Julio Ramirez; Victor Yu
Journal:  Chest       Date:  2004-05       Impact factor: 9.410

9.  Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance.

Authors:  David J Farrell; Stephen G Jenkins; Steven D Brown; Manish Patel; Bruce S Lavin; Keith P Klugman
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

10.  Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Authors:  Lionel A Mandell; John G Bartlett; Scott F Dowell; Thomas M File; Daniel M Musher; Cynthia Whitney
Journal:  Clin Infect Dis       Date:  2003-11-03       Impact factor: 9.079

View more
  3 in total

1.  Pneumonia: macrolides or amoxicillin for community acquired pneumonia?

Authors:  Federico Marchetti; Irene Berti
Journal:  BMJ       Date:  2006-05-20

Review 2.  Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Authors:  Brad Spellberg; George H Talbot; Eric P Brass; John S Bradley; Helen W Boucher; David N Gilbert
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

3.  The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.

Authors:  Josef Yayan
Journal:  Drug Des Devel Ther       Date:  2014-10-03       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.